Insomnia

Insomnia is the most common sleep complaint, affecting roughly 30% of adults occasionally and 10% chronically. The clinical syndrome includes difficulty initiating sleep (sleep onset insomnia), difficulty maintaining sleep (sleep maintenance insomnia, with frequent awakenings), early morning awakening, and non-restorative sleep — often combined. Chronic insomnia drives daytime fatigue, cognitive impairment, mood symptoms, increased cardiovascular risk, and significant quality-of-life impact. Conventional management has shifted from a hypnotic-medication-first approach to cognitive-behavioral therapy for insomnia (CBT-I) as first-line, with pharmacotherapy reserved for selected cases.

The modern insomnia treatment hierarchy: CBT-I (sleep restriction, stimulus control, cognitive restructuring, sleep hygiene) as first-line for chronic insomnia, with multiple RCTs supporting it; pharmacotherapy as adjunct or for short-term use, including dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant), low-dose doxepin, ramelteon, melatonin, and the older z-drugs (zolpidem, eszopiclone) and benzodiazepines (with concern about long-term use).

Peptide therapy for insomnia has been discussed primarily in the context of DSIP (delta sleep-inducing peptide) and epithalon. DSIP is a naturally-occurring peptide identified for its role in promoting delta wave (deep sleep) activity. Epithalon is a Russian-developed pineal-derived tetrapeptide associated with circadian regulation and melatonin. Both have available evidence largely from Russian clinical literature, with limited Western RCT validation. The honest framing: peptides do not replace CBT-I as foundational therapy and have not been validated as effective hypnotic alternatives.

This page covers what's actually known about peptides for insomnia, where the evidence is strongest, how peptide therapy fits alongside CBT-I and conventional pharmacotherapy, and important caveats. It is informational, not medical advice.

How peptides target insomnia

DSIP (delta sleep-inducing peptide) was originally isolated from rabbit cerebral venous blood during electrically-induced sleep states in the 1970s, with subsequent identification of its role in promoting delta-wave (slow-wave) sleep activity. The proposed mechanism involves modulation of brainstem and hypothalamic sleep-regulating circuits. Russian clinical use has explored DSIP in chronic insomnia, particularly stress-related insomnia, with reports of improved sleep architecture and subjective sleep quality. Western evidence is largely preclinical.

Epithalon (the Russian transliteration; epitalon in some sources) is a pineal-derived tetrapeptide developed by Khavinson and colleagues. It is associated with telomerase activity, circadian regulation, and melatonin synthesis. Russian clinical use includes age-related sleep disturbance and circadian disruption, with reports of improved sleep quality. The melatonin-related mechanism is mechanistically aligned with circadian-driven insomnia, particularly age-related sleep disruption.

Selank may have a complementary role for the anxiety component of insomnia. Anxiety-driven sleep onset difficulty is common in chronic insomnia, and Selank's anxiolytic effects without sedation may help reduce sleep-onset anxiety while allowing natural sleep to occur. The mechanism contrasts with benzodiazepines (which sedate but disrupt sleep architecture).

What peptides do not do: replicate the rapid sleep induction of zolpidem or other hypnotics, address sleep apnea or other primary sleep disorders requiring specific intervention, or replace CBT-I as foundational therapy for chronic insomnia.

What the evidence shows

There are no Western randomized trials of DSIP or epithalon for insomnia in patient populations meeting modern diagnostic criteria. Russian clinical literature describes use in chronic insomnia and age-related sleep disturbance with reported benefits. The trial design and reporting standards do not meet Western pivotal-trial expectations.

For evidence-validated comparators: CBT-I has multiple RCTs and meta-analyses supporting it as first-line for chronic insomnia, with effect sizes equal to or greater than pharmacotherapy and durable benefit beyond treatment cessation. Dual orexin receptor antagonists have Phase 3 RCT support with FDA approval. Low-dose doxepin has evidence for sleep maintenance. Melatonin has modest evidence for sleep onset, particularly in circadian-related insomnia. Ramelteon (melatonin receptor agonist) is FDA-approved for sleep onset insomnia.

Peptide therapy is not displacing this evidence base. The reasonable place for peptides is as an adjunct in selected patients, particularly age-related sleep disturbance with circadian features (epithalon) or stress-related insomnia (DSIP, Selank), in patients also engaged with CBT-I and good sleep hygiene.

What to expect

Reports vary widely. Sleep response to any intervention is highly individual. With DSIP (typically subcutaneous injection 30-60 minutes before bedtime, 100-300 mcg, 4-8 weeks): subjective sleep architecture improvement and reduced nocturnal awakenings reported in some users. With epithalon (subcutaneous injection courses of 5-20 days): reports of improved sleep quality and circadian alignment, particularly in older adults with age-related sleep changes. With Selank for anxiety-driven sleep onset insomnia: subjective reduction in pre-sleep anxiety with improved sleep onset.

What to NOT expect: rapid sedation comparable to zolpidem, sleep that approaches normal in patients with primary sleep disorders requiring different management (sleep apnea, restless legs syndrome, narcolepsy), or sustained improvement without addressing the behavioral and cognitive contributors that CBT-I targets.

Frequently asked questions

Part of these goals

Related conditions

• Anxiety
• Chronic Fatigue
• Brain Fog